GlassScriptPhysician profile
Joseph B Garber
NPI 1306910542
$8,063.02
in general payments reported to CMS, 2019-2025
34 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $982 · 2021: $1,330 · 2022: $967 · 2023: $1,044 · 2024: $1,148 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,981.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,847.93 | 2019-2025 | Clareon, Centurion, Argos |
| Allergan, INC. | $627.76 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $579.15 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $517.79 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $445.76 | 2022-2025 | Envista Mx60 Iol, Envista Envy Iol, Stellaris |
| Abbvie INC. | $374.63 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $355.83 | 2019-2021 | |
| Rxsight INC | $331.76 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Harrow Eye, LLC | $264.58 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $241.64 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $226.35 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $180.65 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $152.34 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Amgen INC. | $117.54 | 2025 | Tepezza |
| Glaukos Corporation | $88.43 | 2022-2025 | Idosetr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $84.27 | 2020-2021 | |
| Thea Pharma INC. | $79.79 | 2023-2025 | Iyuzeh |
| Sight Sciences, INC. | $79.50 | 2019-2024 | Omni Surgical System, Tearcare System |
| Biotissue Holdings INC. | $79.35 | 2019-2025 | |
| Astellas Pharma US INC | $56.30 | 2024 | Izervay |
| Shire North American Group INC | $45.37 | 2019 | |
| Lumibird Medical INC. | $30.81 | 2025 | |
| Oyster Point Pharma, INC. | $30.34 | 2024 | Tyrvaya |
| Rayner Intraocular Lenses Limited | $30.09 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Lkc Technologies, INC. | $23.38 | 2025 | |
| Ocular Therapeutix, INC. | $22.99 | 2020 | |
| Mallinckrodt Hospital Products INC. | $22.04 | 2022 | |
| Dompe US, INC. | $21.79 | 2019 | |
| Apellis Pharmaceuticals, INC. | $21.69 | 2025 | Syfovre |
| Tearlab Corp | $18.52 | 2024 | Scoutpro Osmolarity System |
| Akorn Operating Company LLC | $18.50 | 2021 | |
| Horizon Therapeutics Plc | $17.85 | 2022 | |
| Quidel Corporation | $14.64 | 2019 | |
| Heidelberg Engineering, INC. | $13.66 | 2024 | Spectralis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Garber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.